Cash Flow from Operating Activities: A company's cash flows from operations.
Spero Therapeutics, Inc. (SPRO) had Cash Flow from Operating Activities of $-23.44M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$47.98M |
|
$-68.57M |
|
-- |
|
$47.98M |
|
$121.34M |
|
$-73.36M |
|
$4.79M |
|
$-68.57M |
|
$-68.57M |
|
$-68.57M |
|
$-68.57M |
|
$-68.57M |
|
$-68.57M |
|
$-73.36M |
|
$-73.36M |
|
54.04M |
|
54.04M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$107.28M |
|
-- |
|
$3.27M |
|
$110.54M |
|
$49.07M |
|
-- |
|
$15.35M |
|
$64.42M |
|
$46.12M |
|
$46.12M |
|
$46.12M |
|
54.59M |
|
| Cash Flow Statement Financials | |
|
Cash Flow from Operating Activities |
$-23.44M |
-- |
|
-- |
|
$76.33M |
|
$52.89M |
|
$-23.44M |
|
$7.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-152.91% |
|
-152.91% |
|
-152.90% |
|
-142.91% |
|
-142.91% |
|
$-23.44M |
|
-- |
|
-- |
|
-- |
|
0.43 |
|
-- |
|
0.91 |
|
399.23 |
|
-148.66% |
|
-148.66% |
|
-62.03% |
|
-148.66% |
|
$0.84 |
|
$-0.43 |
|
$-0.43 |
|